Ser240

Site Information
FVPGRRAsLsDLtDL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 468620

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 )
Disease tissue studied:	breast cancer ( 7 , 8 , 14 ) , breast ductal carcinoma ( 7 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, triple negative ( 3 , 7 ) , leukemia ( 16 , 33 ) , acute myelogenous leukemia ( 16 ) , chronic myelogenous leukemia ( 33 ) , hepatocellular carcinoma, surrounding tissue ( 24 ) , lung cancer ( 14 , 20 ) , non-small cell lung cancer ( 14 ) , ovarian cancer ( 7 )
Relevant cell line - cell type - tissue:	293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 34 ) , 293 (epithelial) [AT1 (human), transfection] ( 21 ) , 293E (epithelial) ( 18 ) , 786-O (renal) [VHL (human), transfection] ( 5 ) , 786-O (renal) ( 5 ) , A498 (renal) ( 22 ) , A549 (pulmonary) ( 10 ) , breast ( 3 , 7 ) , BT-20 (breast cell) ( 14 ) , BT-549 (breast cell) ( 14 ) , Calu 6 (pulmonary) ( 14 ) , CL1-0 (pulmonary) ( 20 ) , CL1-1 (pulmonary) ( 20 ) , CL1-2 (pulmonary) ( 20 ) , CL1-5 (pulmonary) ( 20 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 15 ) , Flp-In T-Rex-293 (epithelial) ( 15 ) , H2009 (pulmonary) ( 14 ) , H2077 (pulmonary) ( 14 ) , H2887 (pulmonary) ( 14 ) , H322M (pulmonary) ( 14 ) , HCC1937 (breast cell) ( 14 ) , HCC2279 (pulmonary) ( 14 ) , HCC366 (pulmonary) ( 14 ) , HCC78 (pulmonary) ( 14 ) , HCC827 (pulmonary) ( 14 ) , HeLa (cervical) ( 2 , 6 , 31 ) , hepatocyte-liver ( 24 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 8 ) , HMLER ('stem, breast cancer') ( 8 ) , HOP62 (pulmonary) ( 14 ) , HUES-9 ('stem, embryonic') ( 19 ) , Jurkat (T lymphocyte) ( 11 , 17 , 26 , 27 , 35 ) , K562 (erythroid) ( 13 , 33 ) , KG-1 (myeloid) ( 16 ) , LCLC-103H (pulmonary) ( 14 ) , leukocyte-blood ( 25 ) , liver ( 9 ) , LOU-NH91 (squamous) ( 14 ) , MCF-7 (breast cell) ( 14 ) , MDA-MB-231 (breast cell) ( 14 ) , MDA-MB-468 (breast cell) ( 14 ) , NCI-H1395 (pulmonary) ( 14 ) , NCI-H1568 (pulmonary) ( 14 ) , NCI-H157 (pulmonary) ( 14 ) , NCI-H1648 (pulmonary) ( 14 ) , NCI-H1666 (pulmonary) ( 14 ) , NCI-H1703 (squamous) ( 28 , 29 , 30 ) , NCI-H2030 (pulmonary) ( 14 ) , NCI-H2172 (pulmonary) ( 14 ) , NCI-H322 (pulmonary) ( 14 ) , NCI-H460 (pulmonary) ( 14 ) , NCI-H520 (squamous) ( 14 ) , NCI-H647 (pulmonary) ( 14 ) , NT2 (testicular) ( 23 ) , ovary ( 7 ) , PC9 (pulmonary) ( 14 ) , TERT20 ('stem, mesenchymal') ( 32 ) , Vero E6-S ('epithelial, kidney') ( 1 )

Upstream Regulation
Treatments:	ischemia ( 7 ) , metastatic potential ( 20 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
3	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
4	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
5	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
6	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
9	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
10	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
11	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
12	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
13	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
14	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
15	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
16	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
17	Guo A (2011) CST Curation Set: 12455; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V) Curated Info
18	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
19	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
20	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
21	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
22	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
23	Zhou J (2010) CST Curation Set: 9679; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
24	Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9 20166139 Curated Info
25	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
26	Moritz A (2009) CST Curation Set: 7933; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
27	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
28	Moritz A (2008) CST Curation Set: 5783; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
29	Moritz A (2008) CST Curation Set: 5784; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
30	Moritz A (2008) CST Curation Set: 5786; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS/T) Immunoaffinity Beads Cat#: 1984 Curated Info
31	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
32	Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313 18578522 Curated Info
33	Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
34	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
35	Stokes M (2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info